Phil Rinnander

Phil Rinnander is a long-tenured finance executive at Merck & Co., Inc., the global pharmaceutical company headquartered in Rahway, New Jersey (and known as MSD outside the U.S. and Canada). Public professional listings identify his current role as Executive Director, Financial Evaluation & Analysis, with a LinkedIn self-description spanning finance, contracting, and senior-director responsibilities. He is based in the Greater Philadelphia area (King of Prussia, PA), one of Merck's major operational hubs.

Aggregated professional profiles indicate he has held financial leadership roles at Merck since roughly 2005, with experience described across financial management, treasury/business evaluation, and contracting. His work sits on the corporate-finance and commercial side of a large pharma organization — the kind of role that involves internal capital-allocation analysis, deal/contract evaluation, and business-case review rather than external startup investing.

His name has also appeared in the context of Merck's official corporate communications on pharmaceutical pricing matters (e.g., industry correspondence relating to the 340B Drug Discount Program), consistent with a senior finance/contracting function inside the company.

Beyond these professional listings, there is limited public biographical detail available (education and exact role history are not publicly documented from primary sources), and he does not maintain a public investor profile.

• No stated venture/angel investment thesis could be found. Phil Rinnander does not publish an investment thesis, maintain an investor page, or appear on startup-investment platforms (e.g., no AngelList/Crunchbase investor profile surfaced).
• His professional focus is corporate financial evaluation and analysis at Merck — internal deal/contract evaluation and finance leadership — not external equity investing into startups.
• The "Seed Round" stage tag in the source data is not supported by any evidence and should not be relied upon.